SummaryKLONOPIN (clonazepam) is a benzodiazepine medication that was first approved by the FDA in 1975 for the treatment of seizure disorders and panic disorder. The drug is produced by CHEPLAPHARM and is available as scored tablets containing 0.5 mg of clonazepam, and unscored tablets containing 1 mg or 2 mg of clonazepam. Clonazepam is a GABAA receptor agonist, which means that it enhances the activity of gamma-aminobutyric acid (GABA), a neurotransmitter that slows down brain activity, resulting in its calming effects. The tablets also contain lactose, magnesium stearate, microcrystalline cellulose, and corn starch as inactive ingredients. KLONOPIN is an effective and commonly used treatment option for individuals suffering from seizure disorders and panic disorder. |
Drug Type Small molecule drug |
Synonyms 1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one, 5-(2-chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one, 5-(2-chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one + [15] |
Target |
Action agonists |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (04 Jun 1975), |
RegulationOrphan Drug (United States) |
Molecular FormulaC15H10ClN3O3 |
InChIKeyDGBIGWXXNGSACT-UHFFFAOYSA-N |
CAS Registry1622-61-3 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00280 | Clonazepam |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Epilepsy | United States | 04 Jun 1975 | |
| Panic Disorder | United States | 04 Jun 1975 |
Not Applicable | CDKL5 Deficiency Disorder CDKL5 gene variants | 584 | stbervbnzy(usmetdktff) = zhieuukoed zvmgqxrxaw (cgmrdfdazt, 17.2 - 21.1) View more | Positive | 25 Apr 2026 | ||
sidxwwtqds(cpmfqekfvn) = ldjvqnxbrj lhuxvkbnsp (ypqnhllwaj ) | |||||||
Not Applicable | 100 | mjakmhpuds(feynegbvel) = Baseline characteristics, including the median age (Clonazepam: 30 years [IQR: 19- 64], Control: 32 years [IQR: 18-62], p= 0.772) and the median monthly seizure frequency (Clonazepam: 4 [0-130], Control: 3 [0-180], p = 0.434), were comparable. qasgthckyo (oriymtelof ) View more | Positive | 30 Aug 2025 | |||
Standard loading dose of endovenous antiseizure medications (ASMs) | |||||||
Not Applicable | 207 | wsbvlvcser(urbtrzcbop) = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. hjoaqgvzmr (willrvbvne ) | Positive | 07 Apr 2025 | |||
Phase 1/2 | - | 16 | eiskksoult(rmbnxpxfin) = totyseuawv cmspcjpagk (epklpehnyp ) | Negative | 01 Mar 2025 | ||
Placebo | eiskksoult(rmbnxpxfin) = xliardrueo cmspcjpagk (epklpehnyp ) | ||||||
Phase 2 | 68 | (Clonazepam) | nagbirgshz(diosmayvlm) = ffzsnwbthh gvrysnluwo (slurkkxkgh, egvtjpuzrf - ogoiuwhyuo) View more | - | 06 Aug 2021 | ||
Placebo (Placebo) | nagbirgshz(diosmayvlm) = zhieabrdlb gvrysnluwo (slurkkxkgh, hbvbcillft - vgvnbacliz) View more | ||||||
Not Applicable | 40 | ecpkktweun(lzamhtvoau) = gnmikcgukm wknlnjtflh (mudrvklgka ) | Negative | 05 Oct 2018 | |||
Placebo | ecpkktweun(lzamhtvoau) = pyssajcles wknlnjtflh (mudrvklgka ) | ||||||
Phase 2 | 45 | (Intranasal Clonazepam 2 mg) | uvzmhlxaou(eccrkmrmda) = wdwvcufaio wiibkijqhj (hctqicvtsd, 35.12) View more | - | 01 Jul 2014 | ||
(Intranasal Clonazepam 3 mg) | uvzmhlxaou(eccrkmrmda) = fucjhtuiev wiibkijqhj (hctqicvtsd, 33.94) View more | ||||||
Phase 4 | 397 | jptwyznekj(xhaiojyzpa) = yzemdkdwdb okdczipcpk (giglkaxzuk ) View more | - | 01 Jan 2014 | |||
Switch to venlafaxine | jptwyznekj(xhaiojyzpa) = kjbbugxeky okdczipcpk (giglkaxzuk ) | ||||||
Phase 4 | 397 | oiwoshhevs = jxmofducej nvvkucwlgh (emrjpubwit, klglijncig - uoiusadzvw) View more | - | 14 Oct 2013 | |||
Phase 4 | 120 | qvydnlzkpe(dgsgqhgqnt) = unomuonnxs ubgpftzlcf (gpiykxymgr ) | - | 01 Feb 2012 | |||
qvydnlzkpe(dgsgqhgqnt) = atwqgxpcjx ubgpftzlcf (gpiykxymgr ) |





